Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer
详细信息 查看全文
- 作者：Jun-Eul Hwang (1)
Ji-Yun Hong (1)
Karham Kim (1)
Seung-Hun Kim (1)
Won-Young Choi (1)
Min-Jee Kim (1)
Sung-Hoon Jung (1)
Hyun-Jeong Shim (1)
Woo-Kyun Bae (1)
Eu-Chang Hwang (2)
Kyung-Hwa Lee (3)
Jae-Hyuk Lee (3)
Sang-Hee Cho (1)
Ik-Joo Chung (1) - 关键词：Class III β ; tubulin (TUBB3) ; Excision repair cross ; complementation group 1 (ERCC1) ; Taxane ; Stomach neoplasm ; Metastasis
- 刊名：BMC Cancer
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：13
- 期：1
- 全文大小：327 KB
- 参考文献：1. Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. / CA Cancer J Clin 2011,61(4):212-36. CrossRef
2. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. / J Clin Oncol 2006,24(14):2137-150. CrossRef
3. Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, Fleig WE: Chemotherapy for advanced gastric cancer. / Cochrane Database Syst Rev 2005, 2:CD004064.
4. Wu K, Nie Y, Guo C, Chen Y, Ding J, Fan D: Molecular basis of therapeutic approaches to gastric cancer. / J Gastroenterol Hepatol 2009,24(1):37-1. CrossRef
5. Yin M, Hu Z, Tan D, Ajani JA, Wei Q: Molecular epidemiology of genetic susceptibility to gastric cancer: focus on single nucleotide polymorphisms in gastric carcinogenesis. / Am J Transl Res 2009,1(1):44-4.
6. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, / et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. / Lancet 2010,376(9742):9687-697. CrossRef
7. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N: Colorectal cancer. / Lancet 2010,375(9719):1030-047. CrossRef
8. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. / Nat 1979,277(5698):665-67. CrossRef
9. Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V: Signal transduction pathways of taxanes-induced apoptosis. / Curr Med Chem Anticancer Agents 2003,3(4):291-06. CrossRef
10. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LO, Scalabrini-Neto AO: Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. / Am J Clin Oncol 1999,22(6):580-86. CrossRef
11. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS: Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. / Cancer 1999,85(2):295-01. CrossRef
12. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, / et al.: Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). / Ann Oncol 2000,11(3):301-06. CrossRef
13. Constenla M, Garcia-Arroyo R, Lorenzo I, Carrete N, Campos B, Palacios P: Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. / Gastric Cancer 2002,5(3):142-47. CrossRef
14. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E: Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. / J Clin Oncol 2005,23(24):5660-667. CrossRef
15. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, / et al.: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. / J Clin Oncol 2006,24(31):4991-997. CrossRef
16. Hwang J, Cho SH, Shim HJ, Lee SR, Ahn JS, Yang DH, Kim YK, Lee JJ, Kim HJ, Chung IJ: Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. / J Korean Med Sci 2008,23(4):586-91. CrossRef
17. Seve P, Dumontet C: Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? / Lancet Oncol 2008,9(2):168-75. CrossRef
18. Seve P, Isaac S, Tredan O, Souquet PJ, Pacheco Y, Perol M, Lafanechere L, Penet A, Peiller EL, Dumontet C: Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. / Clin Cancer Res 2005,11(15):5481-486. CrossRef
19. Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A, Dumontet C: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. / Mol Cancer Ther 2005,4(12):2001-007. CrossRef
20. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. / N Engl J Med 2004,350(4):351-60. CrossRef
21. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, / et al.: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. / N Engl J Med 2006,355(10):983-91. CrossRef
22. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, / et al.: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. / J Clin Oncol 1998,16(1):309-16.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, / et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. / J Natl Cancer Inst 2000,92(3):205-16. CrossRef
24. Al-Haddad S, Zhang Z, Leygue E, Snell L, Huang A, Niu Y, Hiller-Hitchcock T, Hole K, Murphy LC, Watson PH: Psoriasin (S100A7) expression and invasive breast cancer. / Am J Pathol 1999,155(6):2057-066. CrossRef
25. Dumontet C, Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. / J Clin Oncol 1999,17(3):1061-070.
26. Burkhart CA, Kavallaris M, Band Horwitz S: The role of beta-tubulin isotypes in resistance to antimitotic drugs. / Biochim Biophys Acta 2001,1471(2):O1-.
27. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. / J Clin Invest 1997,100(5):1282-293. CrossRef
28. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR: Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. / Br J Cancer 1998,77(4):562-66. CrossRef
29. Liu B, Staren ED, Iwamura T, Appert HE, Howard JM: Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. / J Surg Res 2001,99(2):179-86. CrossRef
30. Dumontet C, Isaac S, Souquet PJ, Bejui-Thivolet F, Pacheco Y, Peloux N, Frankfurter A, Luduena R, Perol M: Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. / Bull Cancer 2005,92(2):E25-0.
31. Koh Y, Kim TM, Jeon YK, Kwon TK, Hah JH, Lee SH, Kim DW, Wu HG, Rhee CS, Sung MW, / et al.: Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. / Ann Oncol 2009,20(8):1414-419. CrossRef
32. Urano N, Fujiwara Y, Doki Y, Kim SJ, Miyoshi Y, Noguchi S, Miyata H, Takiguchi S, Yasuda T, Yano M, / et al.: Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. / Int J Oncol 2006,28(2):375-81.
33. Lu M, Gao J, Wang XC, Shen L: Expressions of Thymidylate Synthase, Thymidine Phosphorylase, Class III beta-tubulin, and Excision Repair Cross-complementing Group 1predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or Cisplatin. / Chin J Cancer Res 2011,23(4):288-94. CrossRef
34. Kang JH, Lee SI, Lim Do H, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, / et al.: Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. / J Clin Oncol 2012,30(13):1513-518. CrossRef
35. Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, / et al.: Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. / Br J Cancer 2008,98(4):832-39. CrossRef
36. Liu YP, Ling Y, Qi QF, Zhang YP, Zhang CS, Zhu CT, Wang MH, Pan YD: The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. / Oncol Lett 2013,5(3):935-42.
37. Kim JS, Kim MA, Kim TM, Lee SH, Kim DW, Im SA, Kim TY, Kim WH, Yang HK, Heo DS, / et al.: Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. / Br J Cancer 2009,100(5):732-38. CrossRef
38. Napieralski R, Ott K, Kremer M, Specht K, Vogelsang H, Becker K, Muller M, Lordick F, Fink U, Rudiger Siewert J, / et al.: Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. / Clin Cancer Res 2005,11(8):3025-031. CrossRef
39. Smith S, Su D, de la Longrais IA R, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D: ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. / J Clin Oncol 2007,25(33):5172-179. CrossRef
40. Pasini F, Fraccon AP, DEM G: The role of chemotherapy in metastatic gastric cancer. / Anticancer Res 2011,31(10):3543-554.
41. Ando T, Hosokawa A, Kajiura S, Itaya Y, Ueda A, Fujinami H, Nishikawa J, Kobayashi T, Horikawa N, Tsukioka Y, / et al.: Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy. / Gastric Cancer 2012,15(4):427-32. CrossRef
42. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/431/prepub - 作者单位：Jun-Eul Hwang (1)
Ji-Yun Hong (1)
Karham Kim (1)
Seung-Hun Kim (1)
Won-Young Choi (1)
Min-Jee Kim (1)
Sung-Hoon Jung (1)
Hyun-Jeong Shim (1)
Woo-Kyun Bae (1)
Eu-Chang Hwang (2)
Kyung-Hwa Lee (3)
Jae-Hyuk Lee (3)
Sang-Hee Cho (1)
Ik-Joo Chung (1)
1. Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeonnam, 519-763, Korea
2. Department of Urology, Chonnam National University Hwasun Hospital, Jeonnam, Korea
3. Department of Pathology, Chonnam National University Hwasun Hospital, Jeonnam, Korea - ISSN：1471-2407
文摘
Background Class III β-tubulin (TUBB3) is a prognostic marker in various tumors, but the role of TUBB3 in advanced gastric cancer is not clearly defined. We analyzed the significance of TUBB3 expression, along with that of excision repair cross-complementation group 1 (ERCC1) in recurrent and metastatic gastric cancer patients receiving taxane-based first-line palliative chemotherapy. Methods We reviewed the cases of 146 patients with advanced gastric adenocarcinoma who received taxane-based first-line palliative chemotherapy between 2004 and 2010 at Chonnam National University Hwasun Hospital (Gwangju, Korea). Immunohistochemical staining for TUBB3 and ERCC1 was performed using paraffin wax-embedded tumor tissues. We evaluated the patients-response to chemotherapy, progression-free survival (PFS), and overall survival (OS). Results In total, 146 patients with advanced gastric cancer received docetaxel and cisplatin (n--5) or paclitaxel and cisplatin (n--31). The median PFS was significantly shorter for patients with high-level TUBB3 expression than for patients with low-level TUBB3 expression (3.63 vs. 6.67?months, P--.001). OS was not associated with TUBB3 expression (13.1 vs. 13.1?months, P--.769). By multivariate analysis, only TUBB3 was related to a shorter PFS (HR 2.74, 95% CI 1.91-3.91, P--.001). Patients with high-level ERCC1 expression showed a lower response rate than patients with low-level ERCC1 expression (24 vs. 63.2%, P--.001); however, ERCC1 had no clinical effect on PFS or OS. Conclusions TUBB3 was a strong predictive marker in recurrent and metastatic gastric cancer patients receiving taxane-based first-line palliative chemotherapy. No clinical impact of ERCC1 was evident in this setting.